Pichlmayr R, Weimann A, Oldhafer K J, Schlitt H J, Klempnauer J, Bornscheuer A, Chavan A, Schmoll E, Lang H, Tusch G
Klinik für Abdominal- und Transplantationschirurgie, Medizinische Hochschule Hannover, Germany.
World J Surg. 1995 Nov-Dec;19(6):807-13. doi: 10.1007/BF00299775.
Resection remains the treatment of choice in liver cancer. In order to avoid liver transplantation in conventionally unresectable tumors ex-situ ("bench" procedure), in-situ and ante-situm resection technique should be preferred whenever feasible. Despite the deficiency of donor organs, a single center experience with 198 patients reveals that liver transplantation continues its role as a therapeutic option for selected patients. At present "favorable" indications for transplantation are International Union against Cancer (UICC) - stage II hepatocellular carcinoma as well as the subtype fibrolamellar carcinoma, uncommon tumors such as epitheloid hemangioendothelioma, hepatoblastoma, and liver metastases from neuroendocrine tumors. Due to unsatisfying results, intrahepatic bile duct-, stage III and IV hepatocellular carcinoma, hemangiosarcoma, and liver metastases from nonendocrine primaries should be excluded from liver transplantation alone. For these advanced tumors, especially in cases of extrahepatic involvement, a combination of liver transplantation and multivisceral resection has been proven feasible. However, a significant improvement in patient survival may only be expected only by currently investigated multimodality treatment protocols which will require further randomized studies.
肝切除术仍然是肝癌的首选治疗方法。为了避免对传统上无法切除的肿瘤进行体外肝移植(“台式”手术),只要可行,应优先选择原位和术前切除技术。尽管供体器官短缺,但一个拥有198例患者的单中心经验表明,肝移植仍然是部分患者的一种治疗选择。目前,移植的“有利”指征是国际抗癌联盟(UICC)II期肝细胞癌以及纤维板层癌亚型、罕见肿瘤如上皮样血管内皮瘤、肝母细胞瘤和神经内分泌肿瘤的肝转移。由于效果不理想,肝内胆管癌、III期和IV期肝细胞癌、血管肉瘤以及非内分泌原发性肿瘤的肝转移应排除在单纯肝移植之外。对于这些晚期肿瘤,特别是伴有肝外侵犯的病例,肝移植与多脏器切除术联合已被证明是可行的。然而,只有通过目前正在研究的多模式治疗方案才能显著提高患者生存率,而这需要进一步的随机研究。